Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
No, the "1" refers to a single dose, not a one-day cure: Monistat 1 delivers one high-concentration application of miconazole (1200 mg ovule or 4% cream) that stays in the vaginal tissue and keeps working for up to seven days. Most people notice itching and irritation easing within one to three days, while complete clearing of discharge, swelling, and burning commonly takes the full week. Because up to a third of self-diagnosed "yeast infections" are actually bacterial vaginosis, trichomoniasis, or a non-albicans yeast species that resists azoles, a single dose that fails is often a sign the diagnosis, not the drug, was wrong. Timing, pregnancy status, recurrence within two months, and whether you feel a strong burning reaction from the concentrated dose all change what you should do next, and there are several important details to consider below.
If you are unsure whether what you are feeling is yeast, bacterial, or something else entirely, guessing can mean a week of discomfort and a wasted treatment. A free, instant, online symptom check takes only a few minutes, asks the same targeted questions a clinician would, and helps you understand which conditions best match your symptoms and how urgently you should be seen. It is a smart, private first step before you buy another box or book an appointment, so you can walk into the pharmacy or the exam room knowing what to ask.
Last reviewed for medical accuracy: 09/12/2026
Does Monistat 1 Really Cure a Yeast Infection in One Day?
A yeast infection (vulvovaginal candidiasis) affects millions of people each year. Over-the-counter treatments are popular for their convenience—and Monistat 1 promises relief in just one day. But how accurate is that claim? Below, we break down what the research and experts say, what you can expect symptom-wise, and when to seek further care.
Monistat 1 is an antifungal vaginal suppository containing a single high dose (1200 mg) of miconazole nitrate. Miconazole kills yeast (Candida albicans) by disrupting its cell membrane.
Key points:
Several studies and clinical guidelines (including those from the Centers for Disease Control and Prevention and major women’s health textbooks) provide insight into single-dose treatments:
• Efficacy Rates
– Miconazole 1200 mg can resolve symptoms in about 85–90% of uncomplicated yeast infections.
– Success rates are similar to 3-day (200 mg daily) or 7-day (100 mg daily) regimens.
• Symptom Relief Timeline
– Many people report noticeable relief (less itching and burning) within 24 hours.
– Complete eradication of the yeast and full symptom resolution may take up to 3–7 days.
• Recurrence and Retreatments
– Some users experience a return of symptoms within a month.
– Recurrent infections may require prescription—fluconazole pills or longer topical courses.
It helps to distinguish between symptom relief and complete cure:
Symptom relief:
True cure:
Monistat 1 delivers rapid symptom control, but your body may need additional time to heal tissue irritation. Full cure is usually confirmed when discharge returns to normal, discomfort is gone, and no yeast is detected on follow-up exams.
If side effects persist or worsen, stop treatment and speak to a healthcare professional.
Monistat 1 may be a good option if:
Avoid self-treatment if:
See a doctor if you experience:
For a quick assessment of whether your symptoms align with a yeast infection or something else, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. (Link: https://ubiehealth.com/)
Alongside antifungal treatment, these practices can help prevent future yeast infections:
Monistat 1 is a proven, single-dose antifungal that offers many users rapid relief from yeast infection symptoms. While many people feel significantly better within 24 hours, complete cure (elimination of all yeast) may take up to a week. If you have recurrent or severe infections, first-time symptoms, or signs of another condition, seek medical evaluation rather than self-treating.
No matter which treatment you choose, always read and follow the package directions carefully. If any symptom is life threatening or you’re in severe discomfort, please speak to a doctor right away.
(References)
* Miconazole. Aust Nurses J. 1983 Mar;12(8):42-3. PMID: 6552174.
* Kükner S, Ergin T, Ciçek N, Uğur M, Yeşilyurt H, Gökmen O. Treatment of vaginitis. Int J Gynaecol Obstet. 1996 Jan;52(1):43-7. doi: 10.1016/0020-7292(95)02531-6. PMID: 8620988.
* Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011 Aug;20(8):1245-55. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20. PMID: 21774671.
* Pankhurst CL. Candidiasis (oropharyngeal). BMJ Clin Evid. 2012 Feb 20;2012. Epub 2012 Feb 20. PMID: 22348417; PMCID: PMC4429411.
* Pankhurst CL. Candidiasis (oropharyngeal). BMJ Clin Evid. 2013 Nov 8;2013:1304. Epub 2013 Nov 8. PMID: 24209593; PMCID: PMC3821534.
* Taudorf EH, Jemec GBE, Hay RJ, Saunte DML. Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice. J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1863-1873. doi: 10.1111/jdv.15782. Epub 2019 Jul 30. PMID: 31287594.
* Oyom AP, Okello E, Acam V, Aramo C, Mwambi B, Okiria JC, Oyet C. Prevalence and antifungal susceptibility of gastrointestinal candidiasis among diabetic patients: A cross-sectional study. Afr J Lab Med. 2020;9(1):997. doi: 10.4102/ajlm.v9i1.997. Epub 2020 Dec 10. PMID: 33354526; PMCID: PMC7736660.
* Nogueira J, Parente AR, Mendes A, Lavadinho I. Tongue Hematoma With Necrosis. Cureus. 2021 Jan 16;13(1):e12741. doi: 10.7759/cureus.12741. Epub 2021 Jan 16. PMID: 33614342; PMCID: PMC7883558.
* Karakoyun AS, Unal N, Sucu M, Bingöl O, Unal I, Ilkit M. Integrating Clinical and Microbiological Expertise to Improve Vaginal Candidiasis Management. Mycopathologia. 2024 Nov 8;189(6):96. doi: 10.1007/s11046-024-00904-8. Epub 2024 Nov 8. PMID: 39514006.
* Sugio CYC, Martin V, Gonçalves LMD, Ferrari PC, Urban VM, Neppelenbroek KH, Fernandes MH. Antifungal Activity, Cytocompatibility, and Wound Healing Potential of Novel Mucoadhesive Formulations for Oral Drug Delivery. J Biomed Mater Res A. 2025 Oct;113(10):e37990. doi: 10.1002/jbm.a.37990. PMID: 40977589.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.